Table 1

Characteristics of study patients

UA>>UA, n=16RA, n=19UA>>RA, n=8SpA, n=7
Age, years39 (20–67)53 (22–82)54 (43–66)44 (20–56)
Female, n121070
Disease duration, months4 (1–10)5 (1–12)4 (1–11)2 (1–12)
VAS, 0–10063 (9–93)37 (11–99)48 (32–98)35 (17–91)
TJC68, n3 (0–37)16 (5–38)13 (3–25)4 (0–11)
SJC66, n1 (1–19)8 (4–41)6 (1–20)2 (1–5)
ESR, mm/h34 (4–85)32 (3–91)30 (14–77)11 (3–47)
CRP, mg/litre11 (2–58)12 (3–133)173–427 (1–46)
IgM-RF positive, n21310
ACPA positive, n21030
No DMARDs12002
DMARD monotherapy31545
≥2 DMARDs1420
≥2 MTX plus anti-TNF0020
  • Patients were classified as having rheumatoid arthritis (RA) based on 1987 American College of Rheumatology (ACR) criteria. UA>>UA=undifferentiated arthritis (UA) at baseline and at 2 years of follow-up; UA>>RA=classified as having UA at baseline and diagnosed as having RA at 2 year follow-up.

  • ACPA, anti-citrullinated protein antibody; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; IgM-RF, immunoglobulin M rheumatoid factor; MTX, methotrexate; SpA, spondyloarthritis; SJC66, 66-joint swollen joint count; TJC68, 68-joint tender joint count; TNF, tumour necrosis factor α; VAS, visual analogue scale of global disease activity.